University Polyclinic Foundation "Agostino Gemelli" - IRCCS, Complex Operative Unit of Medical Oncology
Welcome,         Profile    Billing    Logout  
 15 Trials 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
WALTER, Thomas
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Active, not recruiting
3
507
Europe, RoW
Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid
Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group
OESOPHAGO-GASTRIC CARCINOMA
12/25
12/25
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting
3
244
NA
Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group
University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy
Unresectable Metastatic Colorectal Cancer
10/28
10/29
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
NIPINEC, NCT03591731: Nivolumab +/- Ipilimumab in Patients with Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Active, not recruiting
2
185
Europe
Nivolumab, Ipilimumab
Intergroupe Francophone de Cancerologie Thoracique, GERCOR - Multidisciplinary Oncology Cooperative Group, Federation Francophone de Cancerologie Digestive
Neuroendocrine Carcinoma
07/21
01/25
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial

Recruiting
2
252
Europe
Unsupervised APA program, Supervised APA program
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreas Cancer, Quality of Life
02/22
08/24
BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
PROFILER, NCT01774409: Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

Recruiting
N/A
10000
Europe
Blood and tumor samples
Centre Leon Berard
Neoplasms
07/25
07/26
Microbio-siNET, NCT06624865: Microbiota and Carcinogenesis of Small-intestine Neuroendocrine Tumors

Not yet recruiting
N/A
75
Europe
Blood and stool sampling
Hospices Civils de Lyon
Small-intestine Neuroendocrine Tumors
10/29
10/29
SENSEO, NCT06643026: Sensory Evaluation of Taste and Smell in Oncology

Recruiting
N/A
200
Europe
Food preference
Hospices Civils de Lyon
Digestive Cancers
02/26
02/26
ADOPT-PRESTAGE, NCT03296150: Study Evaluating the Impact of the Program PRESTAGE

Recruiting
N/A
139
Europe
PRESTAGE
Hospices Civils de Lyon
Cancer, Oral Anticancer Drugs
03/26
03/26
SPECTA, NCT02834884: Screening Cancer Patients for Efficient Clinical Trial Access

Recruiting
N/A
4975
Europe, RoW
RP-1828 IMMUcan, RP-1759 AYA/TYA, RP-1843 Arcagen, RP-1920 BioRadon
European Organisation for Research and Treatment of Cancer - EORTC
All Tumor Types
03/26
03/26
ONCOPRO, NCT03787056: Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Recruiting
N/A
410
Europe
Blood draws
Hospices Civils de Lyon
Cancer, Breast Cancer, Gastric Cancer, Renal Cancer, Prostate Cancer, Melanoma, Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Head and Neck Cancer, Pancreatic Cancer, Ovarian Cancer, Glioblastoma, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, B-cell Lymphoma
01/28
01/28
IMMUCARE-BASE, NCT03989323: A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE

Recruiting
N/A
2000
Europe
Estimation of the incidence of the irAE
Hospices Civils de Lyon
Cancer
07/29
07/29
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Recruiting
N/A
1350
Europe
GERCOR - Multidisciplinary Oncology Cooperative Group
Biliary Tract Cancer
06/30
06/40
Pavel, Marianne
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients With NET

Active, not recruiting
2
78
Europe, US
Surufatinib, HMPL-012, sulfatinib
Hutchmed
Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET
09/24
09/24
CABONEN, NCT04524208: A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3

Active, not recruiting
2
45
Europe
Cabozantinib
Karsten Gavenis
Neuroendocrine Tumors, Neuroendocrine Carcinoma
09/24
10/24
Essler, Markus
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
Schinzari, Giovanni
COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting
3
250
Europe, US, RoW
177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
ITM Solucin GmbH
Neuroendocrine Tumors
06/27
09/27
ETNA-FPG, NCT06402695: Observational Study on GEP-and Pulm-NET Treated at FPG

Recruiting
N/A
650
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neuroendocrine Tumors, Gep Net, Pulmonary Neuroendocrine Neoplasm
12/25
07/26

Download Options